Serina Therapeutics, Inc. (SER) Revenue History
Annual and quarterly revenue from 2016 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
SER Revenue Growth
SER Revenue Analysis (2016–2024)
As of May 8, 2026, Serina Therapeutics, Inc. (SER) generated trailing twelve-month (TTM) revenue of $116,000, reflecting significant decline in growth of -100.0% year-over-year. The most recent quarter (Q3 2025) recorded $0 in revenue, down 100.0% sequentially.
Looking at the longer-term picture, SER's 5-year compound annual growth rate (CAGR) stands at -49.6%, indicating revenue contraction over this period. The company achieved its highest annual revenue of $3.2 million in 2023.
When compared to Healthcare sector peers including PRTA (-58.0% YoY), ACAD (+9.9% YoY), and NRXP, SER has underperformed the peer group in terms of revenue growth. Compare SER vs PRTA →
SER Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| SERCurrent | $116,000 | -100.0% | -49.6% | -30442.9% | |
 PRTA | $10M | -58.0% | +62.6% | -1905.8% | |
 ACAD | $1.1B | +9.9% | +19.4% | 9.8% | |
 NRXP | $1M | - | - | -1324.4% | |
 BIIB | $9.8B | +0.4% | -6.1% | 19.1% | |
 ALNY | $3.7B | +82.6% | +49.8% | 13.5% |
SER Historical Revenue Data (2016–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $56K | -98.2% | $-138,000 | -246.4% | $-17,048,000 | -30442.9% |
| 2023 | $3.2M | +530.6% | $3.1M | 97.1% | $-3,129,000 | -99.2% |
| 2022 | $500K | -83.5% | $500K | 100.0% | $-2,270,368 | -454.1% |
| 2021 | $3.0M | +5528.1% | $3.0M | 100.0% | $-1,631,508 | -53.7% |
| 2020 | $54K | -96.9% | $-1,227,000 | -2272.2% | $-10,407,000 | -19272.2% |
| 2019 | $1.7M | +23.8% | $730K | 42.2% | $-12,559,000 | -726.8% |
| 2018 | $1.4M | -0.6% | $555K | 39.8% | $-10,445,000 | -748.2% |
| 2017 | $1.4M | -15.7% | $719K | 51.2% | $-8,417,000 | -599.5% |
| 2016 | $1.7M | - | $755K | 45.3% | $-12,739,000 | -764.6% |
See SER's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SER Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SER vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSER — Frequently Asked Questions
Quick answers to the most common questions about buying SER stock.
Is SER's revenue growth accelerating or slowing?
SER revenue declined -100.0% year-over-year, contrasting with the 5-year CAGR of -49.6%. TTM revenue fell to $116000.00. This reverses the prior growth trend.
What is SER's long-term revenue growth rate?
Serina Therapeutics, Inc.'s 5-year revenue CAGR of -49.6% reflects the variable expansion pattern. Current YoY growth of -100.0% is below this long-term average.
How is SER's revenue distributed by segment?
SER reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2016-2024 are available for download. Segment mix reveals concentration and diversification trends.